JCAR-018

N/A

Report date: 2026/02/18 20:02:09

Base Information

Drug NameJCAR-018
Drug Alias NameJCAR-018
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionCD22 modulatorsT lymphocyte replacements
TargetsCD22
Therapy Area/IndicationsLymphoma, Large-Cell, AnaplasticLymphoma, FollicularLymphoma, B-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteOpus Bio
China Registration ClassN/A

Develop Information

Active CompaniesOpus BioNational Cancer InstituteJuno Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Large-Cell, AnaplasticLymphoma, FollicularLymphoma, B-Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A